Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $12
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $13 to $12.
Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $13 to $12.
